Back to Agenda
Session 11 Track A: Decentralized Trials and Research: Sustaining the Momentum Post-Pandemic
Session Chair(s)
Courtney Granville, PhD, MPH
Chief Scientific Officer
GO2 For Lung Cancer, United States
The rapid adoption of decentralized trials and research is a silver lining of the coronavirus pandemic. Stakeholders across the medical product development continuum moved to integrate decentralized approaches to maintain continuity and respond to the demands of COVID-19. Many organizations developed processes and practices to integrate new technology, while patients and investigators adapted to new ways to interacting, receiving and delivering care and collecting data. As we emerge from the pandemic, what approaches should be retained and how can our community implement process and procedure that is fit for purpose, taking into account the needs and preferences of all stakeholders?
Learning Objective : - Demonstrate how robust clinical trial processes can be developed and optimised ensuring introduction of new technology into decentralised clinical trials to allow patient centric data collection
- Recognize the impact of decentralization on patients – explain how choice and optionality in clinical trials can be incorporated
- Identify remaining challenges to the adoption of decentralized approaches and recognize ways of overcoming barriers
Speaker(s)
Developing Processes for Patient-Centric Decentralised Clinical Trials
Karla Mackenzie, MS
LEO, Australia
Head of CRA Oceania
The Voice of the Patient in Decentralized Research and Trials
Sarah Krug, MS
CANCER101, United States
Executive Director
Multistakeholder Collaborations to Advance Decentralized Trials and Research
Craig H Lipset, MPH
Clinical Innovation Partners, United States
Managing Partner
Have an account?